Skip to content
ModernDocHealth
Contact

Skip to section

Neurology

What the Latest Research Reveals

Data last updated: 33 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

22%
Cognitive Impairment at 12 Weeks
Persisting after COVID-19 infection
Source: Ceban et al.. Molecular Psychiatry (2022). 10.1016/j.bbi.2021.12.020 | n=12000

KEY FINDINGS

Brain Volume Loss
0.2-2.0%
95% CI: Gray matter reduction in orbitofrontal cortex and parahippocampal gyrus
Source [7]
Ischemic Stroke Risk
+52%
95% CI: HR 1.52 (95% CI: 1.43-1.62)
Source [9]
New Dementia Risk (65+)
+69%
95% CI: HR 1.69 (95% CI: 1.53-1.86)
Source [12]
Autonomic Dysfunction
25-50%
95% CI: POTS-like syndrome in Long COVID patients
Source [21]
Pooled prevalence of cognitive impairment in long COVID populations
25%
95% CI: 95% CI: 23-27
Source [33]
Pooled prevalence of brain fog in long COVID populations
30%
95% CI: 95% CI: 28-32
Source [33]
Brain fog prevalence by gender - females vs males
34% vs 23%
Source [33]
Cognitive impairment prevalence by gender - females vs males
29% vs 21%
Source [33]

THE TIMELINE

Acute Phase

0-4 weeks

Encephalopathy in 7-31% of hospitalized patients; anosmia in 40-80%; acute stroke in 1-3%

Key Event
Neurological manifestations peak

Neurological diagnosis at 6 months

Source: Taquet et al., Lancet Psychiatry 2021

Cumulative Risk with Reinfection

+
+
+

“Reinfection associated with additional risk; cumulative hazard model suggests additive risk”

THE HOPEFUL HORIZON

  • 50-70% of patients show substantial improvement by 12 months[10]
  • Vaccination reduces Long COVID neurological risk by approximately 50%[30]
  • White matter changes may be partially reversible based on limited data
  • Cognitive rehabilitation therapy shows benefit for persistent symptoms

SOURCES

  1. [1]Chou SH-Y, et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19. JAMA Network Open. 2021;4(5):e2112131. DOI (opens in new tab)
  2. [2]Ceban F, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity. 2022;101:93-135. DOI (opens in new tab)
  3. [3]Premraj L, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the Neurological Sciences. 2022;434:120162. DOI (opens in new tab)
  4. [4]Siow I, et al. Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases. 2021;30(3):105549. DOI (opens in new tab)
  5. [5]Nannoni S, et al. Stroke in COVID-19: A systematic review and meta-analysis. International Journal of Stroke. 2021;16(2):137-149. DOI (opens in new tab)

See a problem with the Neurology research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 33 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.